BridgeBio Pharma
BBIO
BBIO
198 hedge funds and large institutions have $8.45B invested in BridgeBio Pharma in 2021 Q1 according to their latest regulatory filings, with 61 funds opening new positions, 91 increasing their positions, 38 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
1% more capital invested
Capital invested by funds: $8.37B → $8.45B (+$81.5M)
4.02% less ownership
Funds ownership: 98.68% → 94.66% (-4%)
16% less call options, than puts
Call options by funds: $20.2M | Put options by funds: $24M
Holders
198
Holding in Top 10
15
Calls
$20.2M
Puts
$24M
Top Buyers
| 1 | +$179M | |
| 2 | +$157M | |
| 3 | +$128M | |
| 4 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$87.9M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$67.1M |
Top Sellers
| 1 | -$213M | |
| 2 | -$8.46M | |
| 3 | -$8.38M | |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$8.26M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$7.76M |